The Trial That Reshaped the Theme
On September 4, 2026, the Lp(a) drug race hit its first real test, and the result was not what the bulls wanted. Novartis (NVS) reported that pelacarsen, its antisense candidate, lowered lipoprotein(a) as intended but did not reduce cardiovascular events compared to placebo in a trial of more than 8,300 patients. The biomarker moved. The outcomes did not.
That single result is the most important fact in Porter Stansberry’s Ignition Point thesis, and it deserves more attention than any single stock pick. It exposed the difference between two things that are easy to confuse: a biomarker and a clinical outcome. Every Lp(a) drug that follows now has to answer for that gap.
Biomarker Versus Outcome, Explained
A biomarker is a measurement. Lp(a) level in the blood is a biomarker. A clinical outcome is something a patient experiences: a heart attack, a stroke, a death, a hospitalization. The entire premise of an Lp(a) drug is that the two are linked, that lowering the particle will lower the events. Pelacarsen’s trial was the first large test of that premise, and it failed to confirm it.
This matters because the bullish case for the theme leaned heavily on dramatic biomarker reductions. When a candidate like zerlasiran posts a 99 percent reduction in Lp(a), the number sounds decisive. But a 99 percent reduction in a biomarker is only valuable if the biomarker drives the outcome. Pelacarsen’s trial is evidence that the link is weaker than the headline numbers suggested.
What Pelacarsen’s Failure Actually Shows
It does not prove that lowering Lp(a) is useless. A single negative trial is not the final word, and there are reasons the trial may have underperformed, from duration to the population studied. But it does move the burden of proof. The next candidates now carry more risk, because the easy assumption, that biomarker reduction equals benefit, has been weakened.
The competitors are still running. Amgen’s olpasiran and Eli Lilly’s lepodisiran are RNAi candidates, and both could still show a cardiovascular benefit even if pelacarsen did not. But investors should now treat that benefit as unproven rather than expected. We lay out the full field in our Lp(a) drug race guide, and the underlying biology in our Lp(a) explainer.
Why This Hits the Pitch Hard
The Ignition Point thesis leans on Lp(a) as the killer application for gene silencing. The core speculative names in the swing sleeve are largely bets on this one target. If the biomarker-to-outcome bridge is shaky, the entire sleeve gets riskier, and that is exactly what the September 2026 result introduced. It does not sink the thesis, but it does sharpen the question every investor should be asking.
What the Next Trials Have to Show
Pelacarsen’s failure resets expectations for every candidate behind it, but it also sharpens what a successful trial would have to demonstrate. A positive Lp(a) trial now needs to show an actual reduction in heart attacks, strokes, or cardiovascular deaths, not just a deeper biomarker cut. That is a much higher bar than the early-stage data most of these companies have been touting.
The competitors still have credible paths to get there. Amgen’s olpasiran and Eli Lilly’s lepodisiran use the RNAi mechanism, which some argue achieves more durable suppression between doses, and both are running the kind of large outcome trials that pelacarsen just finished. If either posts a cardiovascular benefit, it would rehabilitate the entire theme in a single announcement. If they fail the same way, the Lp(a) hypothesis gets harder to sell at any size. Investors should read every future headline in this field through that one question: did the drug cut events, or just the biomarker?
The September readout also puts a specific number in a new light. The promo leans on the 99 percent reduction figure attached to Silence Therapeutics’s zerlasiran, and that number is real as a biomarker result. But after pelacarsen, a bigger biomarker cut is no longer enough on its own to imply a better drug. The hurdle the next candidates face is outcomes, not just deeper suppression.
The takeaway is not to write off the entire field. It is to price the remaining candidates as unproven on outcomes until one of them delivers an event-based win. That stance changes the risk math for the speculative names without abandoning the underlying thesis, and it is the posture a careful reader should bring to the whole Ignition Point pitch.
The Bottom Line
The Lp(a) story is now a harder story than it was before September 2026. Lowering the biomarker is proven. Preventing heart attacks is not. That distinction, biomarker versus outcome, is the difference between a science story and an investment story, and it will define how the rest of this drug class is judged.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.